Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC and AstraZeneca Scoop Prestigious SCRIP Award

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.

The AZ-MRC alliance broke new ground in the way industry collaborates with academia and government to share knowledge and discover and develop new drugs.

Clive Morris, AstraZeneca Vice President, New Opportunities iMed, said:

“We are deeply honoured that our alliance with the MRC has been singled out for its innovative character. This is especially meaningful because our alliance with the MRC has played a leading role in inspiring a new era of collaboration and open innovation in the industry.”

Dr Chris Watkins, Head of Translational Research and Industry Liaison at the MRC, who accepted the award, said:

"It's been an absolute pleasure to work with AstraZeneca throughout our ground-breaking compound collaboration and we feel we've made a real step forward in the way we collaborate with industry. We were really pleased with the quality of science we funded through the partnership and to have this all recognised by a prestigious SCRIP award is the icing on the cake, we're delighted to have won."

SCRIP is one of the world’s leading pharmaceutical and biotech news organisations and its ‘Best Partnership Alliance’ award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics.

The ceremony, which took place on 28 November at London’s Lancaster Hotel, rewarded excellence over the whole range of industry activities, from pharma, biotech and those companies that support them.

The AZ-MRC alliance, in which 22 previously studied AstraZeneca compounds were made available to academic researchers, was announced in December 2011. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC, GSK and Five Leading UK Universities Collaborate
Collaboration to crack difficult disease areas.
Thursday, July 16, 2015
MRC and Wellcome Trust Invest £24m in Cambridge Obesity Institute
The joint venture provides a unique environment linking basic and applied science in metabolic diseases.
Thursday, May 30, 2013
Brain Chemical Finding could Open Door to new Schizophrenia Drugs
New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain.
Friday, October 01, 2010
International Collaboration Brings Stem Cell Clinical Trials a Step Closer
Funding for two ambitious projects aimed at bringing stem cell treatments to the point of clinical trial has been unveiled by the Medical Research Council (MRC) today.
Friday, October 30, 2009
MRC welcomes new blueprint for life sciences
A new Blueprint to put innovation at the heart of healthcare delivery in the UK has been launched by Lord Drayson and Lord Darzi at Imperial College London.
Wednesday, July 15, 2009
New Institute to Study Obesity, Diabetes and Other Metabolic Disorders
A new centre has opened to address the growing threat to public health posed by obesity, diabetes and related diseases. The University of Cambridge, the Medical Research Council and Cambridge University Hospitals NHS Foundation Trust have joined forces to create the unique, innovative Institute of Metabolic Science (IMS).
Friday, August 29, 2008
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!